InvestSMART

Opthea Limited (ASX:OPT)

ALERT: Price-sensitive ASX Announcement for OPT
Current share price for OPT : $0.014 -0.586 (-97.67%)+
Announcement
Release
3 Jun 2026 8:48AM
Price at Release
$0.600
Full Release
download
Summary
Opthea Limited, an Australian biotechnology company, announced its reinstatement to the Australian Securities Exchange (ASX) and provided an update on the development of its OPT-302 treatment for lymphangioleiomyomatosis (LAM), a rare lung disease primarily affecting women. The company aims to leverage its existing scientific and operational resources to address the unmet medical needs in LAM by targeting VEGF-C and VEGF-D signaling pathways. The development program spans 18 months and is divided into three stages, focusing initially on preclinical studies, followed by early human trials, and concluding with clinical proof-of-concept studies. Opthea's strategic focus is supported by substantial existing data and intellectual property, with plans to seek orphan drug designation to benefit from market exclusivity and regulatory incentives. The company is also considering a name change to Ceryvyn Therapeutics Limited to reflect its strategic direction.
Key Points
  • Opthea's securities reinstated on ASX from 3 June 2026
  • Focus on developing OPT-302 for lymphangioleiomyomatosis (LAM)
  • LAM characterized by VEGF-C and VEGF-D signaling
  • Development program includes preclinical and clinical stages
  • Program spans 18 months with a stage-gated approach
  • Opthea seeks orphan drug designation for regulatory benefits
  • Company proposes name change to Ceryvyn Therapeutics Limited
  • Plans to leverage existing data and intellectual property
  • Strategic focus aims to maximize shareholder value in LAM treatment
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.